March 2 (Reuters) - Cadila Healthcare Ltd
* USFDA inspected our formulations manufacturing facility at Baddi from 20th February 2017 to 1st March 2017
* Says product is yet to be manufactured or marketed in the US
* All three observations are related to pre-approval inspection (PAI) for a specific product filed.
* Says there are no observations related to CGMP practices Source text: (bit.ly/2mO6eTl) Further company coverage: